Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic α-synuclein oligomers

29 Jul 2024

Abstract excerpt

α-Synuclein (α-syn) accumulates as insoluble amyloid but also forms soluble α-syn oligomers (αSOs), thought to be even more cytotoxic than fibrils. To detect and block the unwanted activities of these αSOs, we have raised 30 monoclonal antibodies (mAbs) against different forms of αSOs, ranging from unmodified αSOs to species stabilized by lipid peroxidation products and polyphenols, αSOs formed by C-terminally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Neurological disorders and treatments
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39075088
DOI: 10.1038/s41531-024-00747-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic α-synuclein oligomersPMID 39075088Read ↗

Monoclonal antibodies targeting cytotoxic α-synuclein oligomers: molecular properties and diagnostic potentialSemantic proximity Read ↗

Characterization of antibodies that selectively detect α-synuclein in pathological inclusionsSemantic proximity Read ↗

Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology: How specific are the conformation-specific α-synuclein antibodies?Semantic proximity Read ↗

The good and bad of therapeutic strategies that directly target α‐synucleinSemantic proximity Read ↗

Detecting Morphologically Distinct Oligomeric Forms of α-SynucleinSemantic proximity Read ↗

Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody FragmentsSemantic proximity Read ↗

Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding AntibodiesSemantic proximity Read ↗

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit <i>in‐vitro</i> seeded aggregation and toxicitySemantic proximity Read ↗

Modulating the Amyloidogenesis of α-Synuclein.Semantic proximity Read ↗

An scFv Intrabody against the Nonamyloid Component of α-Synuclein Reduces Intracellular Aggregation and ToxicitySemantic proximity Read ↗

ELISA method to detect α-synuclein oligomers in cell and animal modelsSemantic proximity Read ↗

AAV-mediated Expression of a Novel Conformational Anti-Aggregated α-Synuclein Antibody Prolongs Survival in a Genetic Model of α-SynucleinopathiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.